Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the development pipeline by Boyd, Sara E. et al.
 1 
Metallo--lactamases: structure, function, epidemiology, treatment options, and the 1 
development pipeline 2 
 3 
Sara E Boyd1, David M Livermore2, David C. Hooper3, William W Hope1 4 
 5 
1 Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical 6 
Pharmacology, University of Liverpool, Liverpool, L69 3GE 7 
2 Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ 8 
3 Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, 9 
Boston, MA 02114 10 
 11 
Corresponding author: 12 
Dr Sara E Boyd MRCP DTMH MBChB 13 
 Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical 14 
Pharmacology, University of Liverpool, Liverpool, L69 3GE 15 
Telephone: +441517945941  16 
Email: s.e.boyd@liverpool.ac.uk 17 
 18 
Key words: metallo--lactamase, treatment, pharmacology, drug development 19 







Modern medicine is threatened by the global rise of antibiotic resistance, especially among  -26 
negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are 27 
increasingly disseminated worldwide, though particularly in Asia. Many producers have 28 
multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and 29 
more encouragingly, MBLs may be less effective agents of carbapenem resistance in vivo, 30 
under zinc limitation, than in vitro. Owing to their unique structure and function, and their 31 
diversity, MBLs pose a particular challenge for drug development. They evade all recently 32 
licensed β-lactam- β-lactamase inhibitor combinations, although several stable agents and 33 
inhibitor combinations are at various stages in the pipeline. These potential therapies, along 34 
with the epidemiology of producers and current treatment options, are the focus of this 35 
review. 36 
  37 
 3 
Introduction 38 
Antimicrobial therapy is threatened by the global rise of resistance, especially in gram-negative 39 
bacteria (1), where resistance to β-lactams is largely mediated by β-lactamases (2). 40 
Carbapenems evade most β-lactamases but are hydrolyzed by metallo-β-lactamases (MBLs) as 41 
well as by a few active-site serine β-lactamases (SBLs), notably members of the KPC and OXA-42 
48-like groups.  MBLs are chromosomal and ubiquitous in some non-fermenters, including 43 
Stenotrophomonas maltophilia, Aeromonas spp. and Chryseobacterium spp., which are of 44 
modest clinical concern. A minority of Bacteroides fragilis strains have a chromosomal MBL, 45 
CfiA or CcrA, but this is uncommon and only expressed strongly if an upstream insertion 46 
sequence provides an efficient promoter (3). More important are the acquired MBLs that are 47 
spreading among Enterobacterales and Pseudomonas aeruginosa (4); these are associated 48 
with extremely-drug-resistant (XDR) phenotypes, with the producers generally also resistant 49 
to multiple aminoglycosides, fluoroquinolones, and other agents as well as to β-lactams.  50 
 51 
Classification and diversity of metallo--lactamases 52 
β-Lactamases are classified by two major systems. The first is based on substrate profiles and 53 
vulnerability to inhibitors (5), and places MBLs into its Group 3, whereas Groups 1 and 2 54 
comprise SBLs. The second classifies β-lactamases according to their amino acid sequences, 55 
recognising four enzyme classes (6). MBLs form class B whilst SBLs divide among classes A, C 56 
and D (7). The MBLs are structurally and mechanistically dissimilar from SBLs, suggesting a 57 
separate evolutionary origin.  58 
Class B is further divided into three subclasses, B1, B2 and B3, based on differences in 59 
amino acid sequence at the active site, zinc ligands, zinc stoichiometry, loop architecture, and 60 
substrate profiles (8). The important acquired MBLs, comprising the IMP, NDM and VIM types 61 
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fall into subclass B1. They hydrolyze all currently available β-lactam antibiotics except 62 
monobactams (e.g. aztreonam) (9), as do most or all other sub-class B1 or B3 enzymes. In 63 
contrast, the CphA (subclass B2) MBLs of Aeromonas spp. have narrow-spectrum activity 64 
directed exclusively against carbapenems. Irrespective of subclass, MBLs are not inhibited by 65 
clavulanic acid, sulbactam, tazobactam, avibactam or by developmental penicillanic acid 66 
sulfones and diazabicyclooctanes.    67 
The important acquired subgroup B1 MBLs (Table 1) are mostly named based on where 68 
they were first described; thus, for example, Verona Integron-encoded Metallo β-lactamase 69 
(VIM) and New Delhi Metallo β-lactamase (NDM). The first acquired MBL (‘imipenemase’, IMP-70 
1), was reported from clinical isolates of P. aeruginosa and Serratia marcescens in Japan in the 71 
1990s (10) and its family now includes over 85 sequence variants (11). The first VIM enzyme 72 
was found in P. aeruginosa in 1997 (12), with over 69 variants since described (11). NDM – 73 
now the most prevalent MBL in Enterobacterales and A. baumannii – was first identified in 74 
2008 in Klebsiella pneumoniae and Escherichia coli isolates from a patient who had travelled 75 
to Sweden from New Delhi, India (13). Twenty-nine NDM variants have since been described, 76 
(11).  77 
It is easy to be dismissive of the chromosomal subclass B2 and B3 MBLs, but recent 78 
reports highlight Stenotrophomonas maltophilia as a multidrug-resistant pathogen in 79 
immunocompromised hosts (14). S. maltophilia carries a subclass B3 MBL (L1 enzyme), which 80 
is unique among MBLs in having four identical subunits (15),  in addition to a chromosomally-81 
mediated SBL (L2 enzyme). This combination confers resistance to almost all β-lactams, 82 
although minimum inhibitory concentrations (MICs) vary with methodology, because media 83 
affect the expression and/or function of these enzymes (16). Elizabethkingia meningoseptica 84 
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has two chromosomal MBLs, a B1 enzyme (BlaB) and a B3 type (GOB) with the former making 85 
the dominant contribution to resistance (17). 86 
 87 
Genetic support of acquired MBLs 88 
Acquired IMP and VIM enzymes generally are encoded by gene cassettes within class 1 or class 89 
3 integrons. These may be embedded within transposons, allowing insertion into the bacterial 90 
chromosome or plasmids (18). By contrast, the blaNDM gene is not integron-associated and has 91 
been observed on narrow-host-range plasmids belonging to incompatibility group IncF, in 92 
addition to wide-host-range plasmids belonging to IncA/C, IncL/M, IncH and IncN (19–22). K. 93 
pneumoniae and E. coli are the frequent hosts of these plasmids, and  there are particular 94 
associations with K. pneumoniae sequence types (STs) ST11, ST14, ST15 or ST147 and E. coli 95 
ST167, ST410 or ST617 (23). These should not, however, be seen as global epidemic strains 96 
along the lines of K. pneumoniae ST258 variants with KPC carbapenemases, for many are 97 
common STs without carbapenemases. In A. baumannii the blaNDM-1 gene is generally located 98 
within the composite transposon Tn125 and embedded between two copies of a strong 99 
promoter gene ISAba125 (24, 25); it is much less prevalent in this genus than are OXA 100 
carbapenemases (Class D).  101 
B2 and B3 MBLs are generally chromosomally encoded, ubiquitous in their host species 102 
and not transmissible. However, exceptions exist, with horizontal transfer observed. Thus, the 103 
AIM-1 MBL (B3) was initially reported, in 2012, to be encoded by a gene inserted in (and 104 
atypical of) the chromosome of a P. aeruginosa isolate; subsequently, in 2019, it was reported 105 
from K. pneumoniae (26). The blaLMB-1 gene, encoding another subclass B3 enzyme, was 106 
reported to be located on a plasmid in Rheinheimera pacifica where it was flanked by ISCR 107 
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mobilization sequences, implying transfer from some other (unknown) source organism. (27). 108 
Mobilization of blaSMB-1 , encoding a third sub-class B3 enzyme, has occurred similarly (28).  109 
 110 
Structure and catalytic function of MBLs 111 
Irrespective of subgroup, MBLs contain the αβ/βα fold typical of the metallo-hydrolase / 112 
oxidoreductase superfamily (29). The S. maltophilia enzyme has four identical subunits (15), 113 
whereas other MBLs are monomeric. 114 
B1 and B3 MBLs have a shallow active-site groove containing 1 or 2 catalytically 115 
functional divalent zinc ions, flanked by flexible loops (29). In contrast, the B2 enzymes have 116 
an active site that is less accessible and flanked by a helix (30). Except for these consistencies, 117 
MBLs are highly divergent even within subclasses, and have as little as 20% sequence identity 118 
between subclasses (7). 119 
Mechanistically, the zinc ion(s) activate a water molecule, which acts to open the β-120 
lactam ring (31). There is no covalent intermediate, as with SBL-mediated catalysis. Anionic 121 
intermediates have been characterized when MBLs hydrolyze carbapenems (32), but not when 122 
NDM-1 enzymes hydrolyze penicillins or cephalosporins (33). In general, imipenem and 123 
meropenem are similarly good substrate for MBLs: for example, NDM-1 enzyme displays 124 
similar catalytic activity, reflected in values of kcat/Km ratio, for imipenem (0.09M -1 s-1) and 125 
meropenem (0.06M -1 s-1) (34); biapenem is a weaker substrate, owing to high Km values, but 126 
seems unsuitable for high-dose development (35).   127 
Figure 1 illustrates the amino acid residues that bind zinc at the active sites of B1, B2, 128 
and B3 MBLs (8). Crystal structures of B1 enzymes, including IMP-, VIM-, NDM-, and B. fragilis 129 
CcrA, (panel A) reveal two zinc-binding sites (Zn1 and Zn2). The Zn1 site contains three histidine 130 
residues (His116, His118, and His196), whereas the ligands for the Zn2 site are aspartic acid 131 
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(Asp120), cysteine (Cys221), and histidine (His263) (8). There is only one zinc ion in the active 132 
site of the A. hydrophila enzyme (subclass B2, panel B), and two in the active site of the S. 133 
maltophilia enzyme (subclass B3, panel C).  134 
Differences in assay methodology between workers make it difficult to compare 135 
hydrolytic efficiencies for different MBLs. Variation within e.g. the VIM, IMP, SPM and GIM 136 
family appears largely inconsequential (36). Nevertheless, subtle but important evolution 137 
may be ongoing, as illustrated in the NDM family.  Here, experimental data do not define 138 
major differences in the catalytic efficiencies among NDM -1, -3, -4, -5, -6, -7 and -8 enzymes  139 
(37) under standard conditions, but differences are seen under zinc deprivation. Thus, 140 
studies comparing NDM-1, NDM-4 (Met154Leu) and NDM-12 (Met154Leu, Gly222Asp) 141 
demonstrate that the Met154Leu substitution, present in 50% of clinical NDM variants in 142 
some locales, enhances the ability to confer resistance at low Zn++ concentrations (38, 39). 143 
This is potentially important because, as discussed later, zinc is restricted in infection (40) and 144 
its scarcity may impede the ability of classical NDM-1 enzyme to confer clinical resistance.  145 
NDM variants that have increased affinity for zinc (up to ~10-fold decreased Kd, Zn2) display 146 
selective advantages in experiments that mimic zinc scarcity imposed by the host immune 147 
system (41). Perhaps driven by similar pressures, the NDM-15 variant has evolved to function 148 
efficiently as a mono- rather than a bi-zinc enzyme (41). In addition, there are suggestions 149 
that NDM enzymes are evolving to develop greater thermodynamic stability (37). 150 
 151 
Epidemiology and distribution of acquired MBLs 152 
Bacteria with IMP, VIM and NDM enzymes have been identified in a range of community, 153 
hospital, and environmental settings (42).  Their prevalence, and importance relative to serine 154 
carbapenemases varies greatly by country. 155 
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 156 
Indian Subcontinent, Asia and Russia.  The greatest burden of acquired, plasmid-mediated, 157 
MBLs lies in south and south-east Asia (43), where NDM types are prevalent. As already noted, 158 
blaNDM-1 was first identified in bacteria isolated in 2008 from a patient who had travelled to 159 
Sweden from India (44). NDM variants have subsequently been spread worldwide via patient 160 
transfers and travel (45). Epidemiological surveillance has confirmed that NDM-1 and its 161 
variants are widely disseminated throughout India, Pakistan and Bangladesh (46, 47); 162 
moreover, a review of 39 carbapenem-resistant Enterobacterales (CRE) collected in India in 163 
2006-2007 by the SENTRY Antimicrobial Surveillance Program found that 15 harboured blaNDM-164 
1 (48), indicating that it was circulating prior to its ‘discovery’ in 2008. Enterobacterales with 165 
blaNDM were isolated from public tap water in India (49) and in river systems around pilgrimage 166 
sites (42) demonstrating the gene has become established beyond healthcare environments.  167 
In India there is frequent co-carriage with other carbapenemases in Enterobacterales 168 
(50); thus, in 2012, among 113 non-clonal CRE isolates at a Mumbai hospital, 106 produced 169 
NDM enzymes and 21 of these also have a second carbapenemase, most often an OXA-48-like 170 
(n=17) or VIM-type (n=4). Surprisingly, given that most international reports of NDM enzymes 171 
relate to Enterobacterales, P. aeruginosa was the most common MBL host (24%) among 3414 172 
carbapenem-resistant gram-negative bacteria collected from community and hospital settings 173 
in North India (51), with blaNDM-1 (36%) the most prevalent carbapenemase gene followed by 174 
blaVIM (18.4%). 175 
Although KPC is the principal carbapenemase among Enterobacterales (CPE) in China, 176 
a survey across 25 provinces showed that 32% of phenotypic carbapenem resistance in 177 
Enterobacterales was linked to blaNDM-1 (52) whilst a study (2012-16) of clinical Enterobacter 178 
cloacae across three tertiary hospitals found blaNDM-1 to be the most common carbapenemase 179 
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gene (80%), followed by blaIMP-26 (8%) and blaIMP-4 (6%) (53). The importance of IMP MBLs, 180 
particularly IMP-4, in China has been underscored by others; thus, multiple Enterobacterales 181 
species carrying a plasmid encoding IMP-4 enzyme were identified from patients with 182 
epidemiological links to China (54), and surveillance at a Beijing hospital highlighted both IMP-183 
4 and NDM-1 in K. pneumoniae (55). Co-localisation of blaNDM-9 and the plasmid-mediated 184 
colistin resistance gene mcr-1 was seen in an E. coli strain recovered from retail chicken meat 185 
in Guangzhou, China (56). Having been recognized 30 years ago in Japan, IMP-type enzymes 186 
are now endemic there, though not highly prevalent (57). 187 
NDM MBLs are the second-most-prevalent carbapenemases after OXA-48  in the 188 
Middle East, excepting Israel (58, 59). This probably reflects extensive interactions with the 189 
Indian subcontinent. As in India, there is significant penetration of blaNDM into P. aeruginosa, 190 
where a much greater proportion of carbapenem resistance appears to be carbapenemase-191 
mediated than in Europe or the USA. Thus, in the Gulf Cooperation Council countries, blaVIM 192 
was found in 39% of carbapenem-resistant P. aeruginosa isolates (60), with most hosts 193 
belonging to internationally-disseminated high risk clones, including ST235, ST111, ST233, 194 
ST654 and ST357 (60). These lineages seem unusually adept at acquiring extrinsic resistance 195 
genes. In Dubai, 32% of resistant P. aeruginosa isolates produced VIM-type MBLs (61), though 196 
a larger proportion had outer membrane impermeability.   197 
The proportion of carbapenem-resistant P. aeruginosa harboring MBLs in Russia rose 198 
from 4.5% between 2002-04 to 28.7% between 2008-10 (62), largely reflecting the spread of 199 
an XDR blaVIM-2-positive ST235 high-risk clone, also present in Belarus and Kazakhstan (62). 200 
NDM is reported as the predominant carbapenemase among Enterobacterales in St Petersburg 201 
(63, 64), whereas OXA-48 is predominant in Moscow (65). 202 
 203 
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Europe. Although Italy had earlier reported both IMP and VIM enzymes (66), Greece was the 204 
first European country to report extensive dissemination of Enterobacterales with MBLs. 205 
Specifically , K. pneumoniae with VIM carbapenemases were reported from multiple hospitals 206 
in 2003–7,  and multi-locus sequence typing identified three major clonal complexes (CCs); 207 
CC147, CC18 and CC14 among the producers (67). By 2006, 20% of K. pneumoniae isolates 208 
collected from hospital wards and 50% of those from ICUs monitored by the Greek System for 209 
the Surveillance of Antimicrobial Resistance were carbapenem-resistant, largely owing to the 210 
spread of the blaVIM-1 cassette (68). By 2010, KPC had displaced VIM to become the dominant 211 
carbapenemase in Greece, largely through the spread of a K. pneumoniae ST258 variant (69). 212 
Nonetheless, VIM-types remained scattered, and may now be re-emerging due to suppression 213 
of the KPC carbapenemases via the use of ceftazidime-avibactam (70).  214 
Elsewhere in Europe concern about carbapenemases grew following a flurry of press 215 
interest in NDM enzymes from 2008-10, and with the spread of K. pneumoniae ST258/512 216 
lineages with KPC carbapenemases in Italy from 2010. The UK, taken as an exemplar, recorded 217 
a few P. aeruginosa and Enterobacterales with IMP and VIM MBLs before 2008. Thereafter, 218 
Enterobacterales with NDM enzymes increased (46). Most early cases were imports via 219 
patients who had travelled to (and often been hospitalized in) the Indian sub-continent. 220 
Multiple NDM variants have subsequently been reported in the UK, with NDM-1 the most 221 
frequent among Enterobacterales, followed by NDM-5 and NDM-7 (71). In contrast, VIM 222 
variants account for 91% of the (uncommon) MBLs in P. aeruginosa, again associated with 223 
international high-risk clones ST235, ST111, ST233 and ST357 (72).  224 
While referral of CPE isolates to the national reference laboratory has increased 100-225 
fold since 2008, many producers are from screening rather than clinical samples. OXA-48 is 226 
now the fastest-spreading carbapenemase but isolates with NDM enzymes account for 20-25% 227 
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of CPE submitted. A growing minority of these, particularly E. coli, have both NDM- and OXA-228 
48-like enzymes (71, 73). 229 
 In 2012, the European Centre for Disease Prevention and Control launched its 230 
‘European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE)’ project. The 231 
geographic distribution of enzyme types were estimated by national experts across 38 232 
European countries in 2015 (74). A random sample of carbapenem-susceptible and -non-233 
susceptible K. pneumoniae and E. coli subsequently were collected prospectively to determine 234 
the occurrence of carbapenemases (75). The results, published in 2017, revealed SBLs (KPC or 235 
OXA-48 enzymes) were more prevalent than MBLs in most countries but that MBLs were 236 
widely scattered and were the most prevalent carbapenemases among Enterobacterales in a 237 
few countries. Thus, VIM enzymes were the dominant carbapenemases in Hungary and NDM 238 
in Serbia and Montenegro. The prevalence of NDM enzymes in the latter countries tallies with 239 
early descriptions of producers linked to these Balkan states. It is unclear whether these 240 
originated as imports from India or as independent local gene escapes from the unknown 241 
source organism (76).  242 
  243 
North America.  Infections due to Enterobacterales carrying blaVIM-2,  blaVIM-7,  blaIMP-4 and blaIMP-244 
18 genes were recorded in the USA prior to 2005 but, in general, MBLs remained extremely rare 245 
(1, 77).  In 2010, Enterobacterales harboring NDM-1 were isolated from three patients in 246 
different states (78) and, as with many contemporaneous cases in the UK and elsewhere, the 247 
source patients had all recently been in India or Pakistan (21). Subsequent expansion of NDM 248 
enzymes in the US has been less marked than the UK, with KPC carbapenemases becoming 249 
considerably more prevalent. Nevertheless, up to December 2017, 379 CPE with NDM 250 
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carbapenemases were reported to the CDC from 34 States, with just under a third (109) from 251 
Illinois (79), where an outbreak was associated with contaminated endoscopes.  252 
 Enterobacterales with NDM enzymes have been increasing in Canada since 2008 and 253 
these MBLs are now the second-most-common carbapenemases in the country, with a higher 254 
prevalence in the Western Provinces (80). Surveillance conducted between 2007-2015 in 255 
Toronto revealed that, among 291 clinical CPE, 51% had NDM enzymes, and 24% of these 256 
patients had never received healthcare abroad nor travelled to high-risk areas (81), suggesting 257 
the enzymes are established locally. In 2019 a novel MBL, blaCAM-1, was identified from isolates 258 
that were collected in 2007 (82). No subsequent isolates harboring this gene have been 259 
reported. 260 
 261 
Africa.  Paucity of data means the prevalence of CPE carrying MBLs in Africa is difficult to 262 
estimate.  Apparent infrequency may reflect true rarity, limited sampling, or a lack of 263 
infrastructure for accurate detection.  CPE with VIM MBLs nonetheless have been identified in 264 
Nigeria, Morocco, Algeria, Tunisia, Tanzania, and South Africa; and those with NDM enzymes 265 
in Kenya, Nigeria, Morocco, Algeria, Tunisia, Tanzania, and South Africa (83, 84). Infections 266 
caused by Enterobacterales producing MBLs are reported from both imported and local cases, 267 
raising concerns regarding emerging endemicity (85). Those with IMP-type enzymes have been 268 
identified in small numbers in Morocco, Tunisia, and Tanzania, and appear genuinely 269 
uncommon (84). An outbreak caused by Klebsiella spp. carrying blaNDM-5 was reported from a 270 
neonatal unit in Nigeria (86). A concern is that African patients are strongly represented in 271 
medical tourism to India, which is a risk factor for colonisation with Enterobacterales producing 272 
MBLs (87). 273 
 274 
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Rest of the world.  KPC enzymes dominate among carbapenemases from Enterobacterales in 275 
Latin America, with (unusually) some penetration also into P. aeruginosa. Nonetheless, 276 
Enterobacterales with NDM enzymes are endemic in Brazil, with several outbreaks reported 277 
(88). Early case reports of MBL-producing Enterobacterales in Latin America often concerned 278 
Proteeae, including Providencia spp. and Morganella (89, 90), which are infrequent hosts of 279 
blaNDM elsewhere. This creates a treatment issue since these genera are inherently resistant to 280 
polymyxins and newer-generation tetracyclines, which remain options against other MBL-281 
producing Enterobacterales (below).  282 
Unique to South America is the wide distribution in Brazil of P. aeruginosa with SPM-1 283 
MBL (91), principally associated with an ST277 clone. Outcomes of severe infections with this 284 
clone are often poor, reflecting a lack of good treatment options (92). 285 
 Carbapenemases are rare in Australasia, but there is spread of blaIMP-4 among 286 
Enterobacterales (93), as in parts of China. E. cloacae is a major host, with dissemination 287 
mediated by an IncHI2 plasmid (94). Production of IMP-4 enzyme has also been recorded in 288 
Salmonella spp. from domestic pets (95) and seagulls (96), but the significance of this is 289 
uncertain. 290 
  291 
MBL function in resistance, in vitro and in vivo 292 
For many years MBLs were perceived as clinically unimportant chromosomally-encoded 293 
enzymes from non-pathogenic organisms, notably Bacillus cereus (97, 98). This perception 294 
changed with recognition that MBLs confer much of the resistance seen in Chryseobacterium 295 
spp. and E. meningoseptica (99) and with heightened awareness of the morbidity and mortality 296 
associated with S. maltophilia bacteraemia (100, 101). Interest then escalated with the 297 
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discovery and proliferation of acquired MBLs, especially NDM-1, which drew extensive press 298 
coverage in 2010.  299 
Many MBL producers are broadly resistant in vitro and, on this basis, real concern exists 300 
about lack of treatments. On the other hand, there is evidence that in vivo resistance to 301 
carbapenems may be less than it appears in vitro, because susceptibility tests are 302 
conventionally done in media (e.g. cation-adjusted Mueller-Hinton broth) with high zinc 303 
concentrations (102), whereas the host immune system imposes a state of zinc deprivation in 304 
infection (40, 103). This lack of zinc may not only impede the catalytic function of MBLs but 305 
may also interfere with their protein folding (102) and may promote degradation of the 306 
enzyme in the periplasm (104).  307 
Several preclinical studies suggest a disconnect between high-level in-vitro resistance 308 
to carbapenems associated with NDM-1 enzymes, but a weak ability to protect against 309 
carbapenems in standard murine infection models (105). Moreover, NDM enzymes appear less 310 
effective than other carbapenemases in causing resistance to carbapenems in patients (106, 311 
107). Thus, mortality in severe infections due to Enterobacterales with blaNDM appears 312 
relatively low, ranging from 13% (108) - 55% (109), when compared to that seen with bacteria 313 
expressing other MBLs  (18% to 67%) (13), or KPC carbapenemases (41% to 65%) (110, 111). 314 
Good clinical outcomes have been reported despite treatment with agents to which NDM 315 
enzymes confer resistance in vitro (106, 107, 112). As yet, there are no studies that confirm or 316 
refute whether the higher numbered NDM alleles, encoding variants with their greater affinity 317 
for zinc (above), are better able to cause clinical resistance than NDM-1 (39, 41).   318 
Finally, it should be underscored that whilst these indications that NDM MBLs are less 319 
potent in vivo are intriguing, they should be approached with caution. Double-blinded 320 
randomized-controlled trials have not been conducted, and existing outcome data are subject 321 
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to various biases (113, 114). For VIM MBLs, clinical outcomes correlate with carbapenem MICs, 322 
implying little or no such in vitro/in vivo discordance (115).  323 
 324 
Current treatment options  325 
Limited data exist to inform clinicians on the optimal treatment for infections caused by MBL-326 
producing gram-negative bacteria (106). Co-trimoxazole remains the standard of care for 327 
infections due to S. maltophilia, but most Enterobacterales with acquired MBLs also have sul 328 
and dfr genes, conferring resistance. Resistances to fluoroquinolones and aminoglycosides are 329 
often present alongside genes encoding acquired MBLs. In particular, blaNDM genes are often 330 
linked to the genes encoding ArmA or RmtB methyltransferases, which modify ribosomes to 331 
block binding of aminoglycosides, including plazomicin; blaIMP and blaVIM generally occur within 332 
integrons that often also carry aac(6’), encoding an acetyltransferase that compromises 333 
amikacin and tobramycin, though not gentamicin or plazomicin (116). A thorough review of 334 
treatment options for MDR and XDR Enterobacterales is available (117). This highlights 335 
observational studies comparing monotherapy to combination therapy for bloodstream 336 
infection (BSI) involving CRE, although few of these were specifically identified as having MBLs 337 
(118, 119).  338 
 339 
Colistin.  Colistin is the current mainstay of treatment for infections due to MBL-producers. A 340 
multinational survey of MBL-producing Enterobacterales and P. aeruginosa conducted from 2012-341 
2014 found >97% susceptibility among MBL-producing P. aeruginosa (variously with IMP-, VIM- 342 
and NDM- enzymes), and >85% for MBL-producing Enterobacterales (>86.1% NDM-type, 343 
>88.9% IMP-type >88.9% IMP-type) (83). Exceptions are Proteeae and Serratia spp., which 344 
have intrinsic polymyxin resistance.  345 
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For bacteria harboring KPC and OXA-48 carbapenemases, colistin has recently been 346 
shown less effective than microbiologically-active β-lactamases inhibitor combinations (120), 347 
making it plausible that an active β-lactam likewise would be more efficacious than colistin 348 
against MBL producers. Of note, the emergence of colistin resistance during treatment, with 349 
secondary transmission of resistant variants is a concern (121, 122).   350 
 351 
Tigecycline, omadacycline and eravacycline.  These tetracyclines have strong in vitro activity 352 
against many MBL-producing Enterobacterales, except Proteeae, although not against P. 353 
aeruginosa. During November 2018, 275 unique Enterobacterales isolates carrying blaNDM 354 
collected by the US Centers for Disease Control were tested with tigecycline (86.5% 355 
susceptible, based on a ≤2 g/ml FDA breakpoint), eravacycline (66.2% susceptible, based on 356 
a ≤0.5 g/ml FDA breakpoint) and omadacycline (59.6% susceptible, based on a ≤4 g/ml 357 
breakpoint) (123). The higher susceptibility rate  for tigecycline than eravacycline reflects the  358 
higher FDA breakpoint for Enterobacterales; in Europe both agents have an identical 0.5 g/ml 359 
breakpoint and eravacycline is the more active on a simple gravimetric basis, though it is 360 
unclear whether this confers clinical advantage (124). Merits of omadacycline are its minimal 361 
known drug interactions and that it can be administered orally (125), however, it has the least 362 
relevant license (for community-acquired bacterial pneumonia and acute bacterial skin and 363 
skin structure infections) in relation to the clinical burden of MBL producers. 364 
  Whilst the in vitro activity of these tetracyclines is encouraging, there are multiple 365 
caveats. First, tigecycline carries an FDA ‘black box’ warning of increased mortality when the 366 
drug was used as monotherapy (126); second, both tigecycline and eravacycline have failed to 367 
achieve non-inferiority to comparators in one or more clinical trials (VAP and diabetic foot 368 
infection for tigecycline, cUTI for eravacycline); third, there is little provenance for tetracyclines 369 
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as monotherapy in the severely-ill patients who commonly develop infections due to MBL-370 
producing opportunists; fourth, particularly for tigecycline, the disparity between EUCAST (S 371 
<0.5 g/ml) and FDA (S <2 g/ml) breakpoints creates categorization uncertainty; last, the lack 372 
of anti-Proteeae activity is important in Latin America, where Providencia spp. are frequent 373 
hosts of blaNDM (127). Given these uncertainties, the best advice is to consider these 374 
tetracyclines in combination against MBL producers, not as monotherapy.   375 
 376 
Aztreonam.  Aztreonam is stable to MBLs, though activity is lost against organisms that co-377 
produce ESBLs or AmpC enzymes (128), which are common in MBL-producing 378 
Enterobacterales. Clinical experience as monotherapy is lacking for MBL producers, although 379 
some success has been recorded when aztreonam was used in combination with ceftazidime-380 
avibactam (129, 130), with avibactam serving to inhibit ESBLs. Six out of ten patients survived 381 
following treatment with this combination during an outbreak of K. pneumoniae with NDM-1, 382 
OXA-48, and CTX-15 β-lactamases in Barcelona (129). Although no adverse events were 383 
reported, the safety is unclear, and it is difficult to match the 1.5g +0.5g q6h regimen of 384 
aztreonam-avibactam that is presently being developed (below). 385 
 386 
Fosfomycin.  Fosfomycin commonly retains full in vitro activity against MBL-producing 387 
Enterobacterales, and has been successful trialed, very recently, as an IV agent in cUTI (131). 388 
It may be an option against MBL producers - particularly E. coli, which is more susceptible than 389 
other Enterobacterales - but it is mainly advocated for use in combination due to concerns 390 
about emergence of resistance, particularly in Klebsiella spp. (132). Fosfomycin has little direct 391 
antipseudomonal activity, with typical MICs above breakpoints. However, in vitro synergy is 392 
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seen when fosfomycin is combined with meropenem against MBL-producing P. aeruginosa 393 
strains (133), suggesting a need for in-vivo exploration. 394 
 395 
Development Pipeline 396 
The development pipeline represents four main strategies against MBL producers: (i) 397 
protection of MBL-stable-monobactams from other co-produced β-lactamases, as e.g. with 398 
aztreonam-avibactam; (ii) development of β-lactams stable to MBLs as well as SBLs, as with 399 
e.g. cefiderocol and BOS-228, (iii) combinations of cephalosporins and carbapenems with 400 
triple-action diazabicyclooctanes (DBOs), and (iv) direct inhibition of MBLs with cyclic 401 
boronates, thiols, chelators, dicarboxylic acids, and other agents.  402 
 403 
Aztreonam-avibactam  404 
Aztreonam-avibactam is the first antibiotic to be developed under a public-private partnership 405 
agreement (134, 135), with partial finance from the European Union’s Innovative Medicine’s 406 
Initiative and, latterly, also the US Biomedical Advanced Research and Developmental 407 
Authority (BARDA).  A prospective randomized phase 3 study (NCT03580044) begins in 2020 408 
to determine efficacy, safety, and tolerability versus best available therapy (BAT) for 409 
hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia 410 
(NP), complicated UTI, or BSI due to MBL-producing gram-negative bacteria (135).  411 
Aztreonam evades hydrolysis by MBLs (128) but is compromised by the ESBL and AmpC 412 
enzymes that are co-produced by many MBL-positive CPE. These SBLs are inhibited by 413 
avibactam, a diazabicyclooctane (DBO) (136, 137) and, consequently, MBL-producing 414 
Enterobacterales that also carry ESBLs or AmpC are susceptible to aztreonam-avibactam in 415 
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vitro (138) and in vivo (139). The combination is less reliably active against MBL-producing P. 416 
aeruginosa (140), because aztreonam has weak anti-pseudomonal activity.  417 
Considerable interest exists, because the safety and efficacy of aztreonam are well 418 
established, and because avibactam was established to be effective at inactivating ESBLs and 419 
AmpC enzymes during trials with ceftazidime. Moreover, case reports suggest success against 420 
infections caused by MBL producers when aztreonam was co-administered with ceftazidime-421 
avibactam (see aztreonam section above) (129, 130).  422 
 423 
MBL-stable -lactams 424 
Cefiderocol (S-649266).  Cefiderocol (S-649266) is a novel parenteral siderophore 425 
cephalosporin designed by Shionogi & Co. Ltd., with a catechol linked to its 3-position side 426 
chain. It is licensed in the USA for cUTI and in the EU and UK for ‘treatment of infections due 427 
to aerobic gram-negative organisms in adults with limited treatment options’ (141). It is 428 
retained among developmental agents here, rather than being included in the established 429 
treatments, because there is little published experience with MBL producers to date (142, 430 
143).  431 
Critically, the catechol moiety forms a chelation complex with ferric iron and this 432 
complex is actively accumulated by gram-negative bacteria, which are forced to scavenge this 433 
essential element (144). Cefiderocol has good activity in vitro under iron starvation, against 434 
gram-negative bacteria, including CPE, P. aeruginosa and A. baumannii (145). It is relatively 435 
stable to both SBLs and MBLs (144), however, the MICs for Enterobacterales and non-436 
fermenters with NDM carbapenemases tend to be slightly higher than those for isolates of the 437 
same species with other carbapenemase types (146). Cefiderocol proved effective against 438 
carbapenem-resistant P. aeruginosa (expressing IMP-1 enzymes), A. baumannii (expressing 439 
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OXA-51-like enzymes) and K. pneumoniae (expressing NDM-1 enzymes) in immunocompetent 440 
rat respiratory tract infection models, achieving a ≥3-log reduction in the number of viable 441 
bacteria in the lungs when dosed over 4 days so as to recreate the human exposures of a 2g 442 
q8h 3h-IV infusion regimen (147). Efficacy reduced when the infusion time was reduced to 1h, 443 
owing to a lower percentage of the dosing interval during which free-drug concentrations were 444 
above the MIC (% Tf >MIC) (147). Interestingly, the mean % Tf >MIC required for a 1-log10 445 
reduction was 18-24%  greater for A. baumannii isolates (expressing OXA-23 or OXA-24) in the 446 
murine lung infection model than for Enterobacterales expressing NDM-1, NDM-4 or KPC-2 447 
enzymes and for P. aeruginosa isolates expressing IMP-1 or VIM-10 MBLs (148). 448 
 In humans, the 2g IV q8h 3h-infusion regimen provided >90% probability of target 449 
attainment (PTA) with 75% Tf >MIC for MICs of ≤4g/ml for patients with normal renal function 450 
(149). A phase 3 trial (NCT03032380) has shown non-inferiority to meropenem in nosocomial 451 
pneumonia (150). Less encouragingly, another trial (NCT02714595), found excess deaths in the 452 
cefiderocol arm, compared with ‘best available therapy,’ for patients with severe infections 453 
caused by carbapenem-resistant gram-negative pathogens (151). Full analysis is awaited but, 454 
notably, deaths were mostly associated with Acinetobacter infections (152), not 455 
Enterobacterales.   456 
  457 
BOS-228 (formerly LYS228).  BOS-228 is a monobactam and, like aztreonam, is stable to MBLs 458 
(153). Unlike aztreonam, it is also stable to many potent SBLs, including carbapenemases, 459 
ESBLs, and AmpC types (154); moreover it binds strongly to PBPs1a and 1b of Enterobacterales 460 
as well as to PBP3, which is the sole target of aztreonam (155). BOS-228 had an MIC90 of 2 461 
g/ml for a clinical panel of 88 Enterobacterales isolates expressing ESBLs, KPCs and MBLs 462 
(153) and no single-step mutants were selected from 12 β-lactamase-expressing 463 
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Enterobacterales exposed to the drug at 8 x MIC, though mutants were selected from 2/12 464 
strains, neither of which expressed MBLs, at 4 x MIC (155).   465 
A randomized evaluator-blinded multi-center phase 2 trial (NCT03354754) to evaluate 466 
pharmacokinetics, clinical responses, safety, and tolerability of BOS-228 in cIAI commenced in 467 
2018. The drug is being administered as IV monotherapy (without metronidazole) q6h for at 468 
least 5 days and compared to standard of care, with outcomes evaluated at day 28. A 469 
randomized controlled evaluator-blinded multi-center trial (NCT03377426) in cUTI has also 470 
been initiated.  471 
 472 
Cephalosporins or carbapenems combined with triple-action DBOs 473 
Zidebactam and nacubactam. Unlike with cyclic boronates (see below), it has not been possible 474 
to discover DBOs that directly inhibit MBLs. However, nacubactam and zidebactam are DBO 475 
analogs that combine inhibition of SBLs with direct antibacterial activity by inhibiting PBP2 476 
(156). When combined with PBP3-targetted β-lactams, this attack on PBP2 leads to an 477 
‘enhancer’ effect, with further β-lactamase-inhibition-independent synergy observed (156, 478 
157). Consequently, cefepime-zidebactam and cefepime- or meropenem- nacubactam 479 
combinations are active in vitro against >75% of MBL-producing Enterobacterales and, in 480 
cefepime-zidebactam’s case, also against many MBL-producing P. aeruginosa (158).  481 
Although the direct antibacterial activity of nacubactam and zidebactam  is readily lost 482 
via mutations compensating for inhibition of PBP2 (159), the enhancer effect is retained, with 483 
many of the mutants consequently remaining susceptible to e.g. cefepime-zidebactam or  484 
meropenem-nacubactam at low concentrations (156, 157). Cefepime-zidebactam is currently 485 
the most advanced of these combinations, with a phase 3 trial due to commence (160). 486 
 487 
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Direct inhibitors of MBLs. 488 
Cyclic boronates - VNRX-5133 (taniborbactam) and QPX7228.  Inhibitors that target both SBLs 489 
and MBLs are of great interest but have proved difficult to obtain owing to structural and 490 
functional differences between and among these enzymes. This combination of inhibitory 491 
activities nonetheless has recently been achieved with several cyclic boronates, notably 492 
taniborbactam and QPX7228. These mimic the tetrahedral anionic intermediate common to 493 
SBL and MBL catalysis (161) and additionally inhibit some penicillin-binding proteins (e.g. PBP-494 
5, which is non-essential) by the same mechanism (162). They represent a considerable 495 
expansion in spectrum over vaborbactam, their progenitor, which inhibits only few class A β-496 
lactamases, notably KPC types (163).  497 
 Taniborbactam (VenatoRx) is the more advanced of these two ‘second-generation’ 498 
boronates, and is in Phase III trials combined with cefepime (164). It irreversibly inhibits class 499 
A, C, and D SBLs, and is a reversible competitive inhibitor of VIM and NDM MBLs, though not 500 
of IMP types (165). Safety has been established in healthy volunteers (NCT02955459), and the 501 
FDA has allowed cefepime-taniborbactam to proceed via fast track pathway for the clinical 502 
indications of cUTI and cIAI.   QPX7728 (QPEX) likewise inhibits both SBLs and MBLs: 50% 503 
inhibitory concentrations [IC50], for KPC enzymes are around 2.9 ± 0.4 nM, compared with 22 504 
± 8 nM for the class C cephalosporinase of E. cloacae P99, 55 ± 25 nM for the NDM-1 MBL and 505 
14 ± 4 nM for VIM-1 enzyme. As with taniborbactam, the IC50 for IMP-1 enzyme is considerably 506 
higher, at 610 ± 70 nM) (166). An IV combination of QPX7728 with meropenem is being 507 
explored. This significantly lowered bacterial counts in murine thigh and lung infection models 508 
with carbapenem-resistant K. pneumoniae, P. aeruginosa and A. baumannii when compared 509 
to meropenem alone, although strain genotypes were not reported. Unlike taniborbactam, 510 
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QPX7228 is orally bioavailable and combinations with ceftibuten and tebipenem were 511 
evaluated in vitro against CPE, including those with MBLs (167).  512 
 513 
Thiol-containing MBL inhibitors and chelating agents.  Small molecules that bind and/or 514 
chelate zinc ions include thiols, dicarboxylates, hydroxamates, and tetrazoles; these are widely 515 
reported to inhibit MBLs, but human metallo-proteases are vulnerable too, so toxicity may 516 
preclude clinical development.  517 
Thiol-containing compounds inhibit all MBL subtypes (B1, B2 and B3) (168), with strong 518 
competitive inhibition of IMP-1 by thioester derivatives first reported in 1999 (169). The 519 
dipeptide L-captopril deserves mention in context. It is used as an ACE inhibitor in the 520 
treatment of hypertension and is reported also to inhibit MBLs by chelating the active site zinc 521 
ions via its thiol group (170); the corresponding  D- stereoisomer is a more potent inhibitor and 522 
can potentiate meropenem against strains with VIM-2 MBLs (170). Both captopril isomers act 523 
via zinc chelation and repurposing is attractive given the known safety of the L-isomer at its 524 
licensed dose; however the economic model for development is yet to be established and 525 
safety issues for the D-isomer need exploration. Other thio-carbonyl compounds, such as 526 
thiomandelic acid, exhibit synergy with meropenem against Enterobacterales with VIM, NDM, 527 
and IMP enzymes (171).  528 
Bisthiazolidines are carboxylate-containing bicyclic compounds, considered to be 529 
penicillin analogs that inhibit MBLs through a zinc-bridging thiol group and a carboxylate that 530 
interacts with K224 (172). The orientation of the carboxylate and thiol moieties create diverse 531 
binding that is observed on X-ray crystal structures and has been shown to inhibit all MBL types 532 
(173). The bisthiazolidine scaffold inhibits NDM-1 enzymes in vitro, with Ki values in the low 533 
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micromolar range (from 7 ± 1 to 19 ±3 M); they restore imipenem activity against E. coli 534 
producing NDM-1 (172). 535 
The divalent cation chelator EDTA has raised interest, too, both as an inhibitor of MBLs, 536 
and also because it disrupts the gram-negative outer membrane and neutralizes various 537 
bacterial enzymes and toxins (174, 175). It is widely used in identification tests for MBLs.  538 
Sodium calcium EDTA, which is licensed for use for treatment of lead poisoning, reportedly 539 
restored imipenem’s activity in vivo against P. aeruginosa producing IMP- and VIM- enzymes 540 
and against  E. coli producing NDM-1 enzyme (176, 177), raising the issue of whether it might 541 
be used to potentiate carbapenems in human infections.  Elores®, which is marketed in India, 542 
combines ceftriaxone, sulbactam and EDTA (178, 179) and reportedly achieved cures of 543 
infections due to MBL producers in multiple patients, with no serious adverse events (178). 544 
However, prospective and controlled studies are lacking, the dose of EDTA is low, and there 545 
remains uncertainty (above) about the function of NDM-1 enzyme in vivo. More negatively, 546 
the FDA has placed strict limits on the amount of EDTA permissible even in food (180) and 547 
sodium calcium EDTA is capable of producing toxic effects that can be fatal (181). High 548 
concentrations of EDTA are likely to strip divalent cations from human metalloenzymes, 549 
including matrix metalloproteinases, carbonic anhydrase and carboxypeptidases, thus limiting 550 
clinical applicability.   551 
Aspergillomarasmine A (AMA) is a fungal natural product discovered in the 1960s (182), 552 
and re-evaluated in the 1980s as an inhibitor of the human metalloproteinase angiotensin-553 
converting enzyme (ACE). AMA inhibits MBLs via a metal ion sequestration mechanism and 554 
displays rapid and potent inhibition of NDM-1 and VIM-2 enzymes in vitro (183). It restored 555 
the activity of meropenem against a K. pneumoniae strain expressing NDM-1 enzyme in an 556 
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intraperitoneal murine infection model (184).  Again, the hazard of inhibiting human metallo-557 
enzymes requires careful investigation. 558 
 559 
Challenges for the development of inhibitors of MBLs 560 
One of the biggest challenges in designing MBL inhibitors is the diversity among these enzymes, 561 
which share less than one third sequence identity at their active sites. Thus, for example, 562 
taniborbactam and QPX7728 target NDM and VIM enzymes, but not IMP types (185). 563 
Development of inhibitors that bind remotely from the active site might overcome this 564 
limitation, but possible target areas also vary within class B1 and seem even better able to 565 
tolerate mutations than the active site (29). Another challenge is the shallow binding site in B1 566 
enzymes, meaning that inhibitors can only make limited interactions (29). Specificity for 567 
bacterial MBLs is a further recurring challenge; interactions with human metallo-enzymes and 568 
contingent toxicity are major concerns. Molecules that solely inhibit MBLs are limited by the 569 
fact that many MBL producers also co-produce SBLs, including carbapenemases, meaning that 570 
the partner β-lactam must evade these enzymes, that the inhibitor must inactivate both MBLs 571 
and SBLs, or that a second inhibitor is required. 572 
Preclinical development is challenging, too, because it is difficult to establish reliable 573 
animal models in which MBL-mediated resistance is expressed, perhaps owing to the already-574 
mentioned lack of essential zinc at infection sites.  Moreover bacteria are prone to lose MBL-575 
encoding plasmids, or fail to reliably express them, in murine models, resulting in 576 
pharmacodynamic data that suggest meropenem susceptibility (186, 187). Consequently it is 577 
difficult to establish the efficacy of candidate MBL-stable drugs or inhibitor combinations. It is 578 
unclear if the same phenomena occur in patients (188), and this requires further research. 579 
Irrespective of this aspect, it is also challenging to find and recruit the required number of 580 
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patients with MBL-producing pathogens to clinical trials. Rapid diagnostics should help, but 581 
their use is complicated by cost and the need to deploy them to all trial sites, including in 582 




MBLs are disseminating internationally, particularly in Asia, and often are produced by gram-587 
negative bacteria with extremely broad spectra of in vitro resistance. Unlike for KPC and OXA-588 
48-like carbapenemases, producers are typically not susceptible to recently licensed β-589 
lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam, 590 
imipenem-relebactam, although cefiderocol may be a potential answer. The ability of MBLs to 591 
confer resistance to carbapenems may not be so great in vivo as in vitro, though this is 592 
uncertain and may vary by enzyme type even within MBL subclasses.    593 
 Inhibitors are known, and the developmental boronates, taniborbactam and QPX7728 594 
are of particular interest. Nonetheless, the quest for effective inhibitors is complicated by 595 
differences in active site structure and zinc ligand interactions among MBLs, and by difficulties 596 
in the design of appropriate preclinical and clinical trials. Non-boronate inhibitors face toxicity 597 
issues, particularly if they interact with other metallo-enzymes or are general chelators. Other 598 
approaches to overcoming MBLs include, avibactam-protected aztreonam; stable β-lactam, 599 
notably BOS-228 as well as cefiderocol, and combinations of β-lactams with-triple action DBOs, 600 
notably cefepime-zidebactam and meropenem-nacubactam.   601 
And that is the positive aspect on which to close: there is now a diverse and exciting 602 
pipeline of potential agents for the treatment of infections caused by bacteria that produce 603 
MBLs. It remains to be seen what will be the most effective of these agents. 604 
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Table 1 Examples of chromosomal and plasmid-associated MBLs (11) 1284 
 1285 
Chromosomal MBLs Plasmid-associated MBLs  
Species Enzyme Subclass Enzyme Subclass 
Bacillus cereus  BcII B1 Verona integron-
















B1 Sao Paulo metallo-
-lactamase (SPM) 
B1 
Bacteriodes fragilis* CfiA / 
CcrA 
B1 German 
imipenemase (GIM)  
B1 
Aeromonas spp.  CphA B2 KHM B1 
Stenotrophomonas 
maltophilia  













Figure 1. Structure of amino acid residues in metallo-β-lactamase enzyme subclasses (8) 1290 
(Reproduced with permission from John Wiley and Sons Publishers, sourced from Palzkill T et 1291 
al. 2013. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277:91–104) 1292 
 1293 
Figure 1 illustrates the amino acid residues that bind zinc at the active sites of B1, B2, 1294 
and B3 MBLs. Crystal structures of B1 enzymes, including IMP-, VIM-, NDM-, and B. fragilis 1295 
CcrA, (panel A) reveal two zinc-binding sites (Zn1 and Zn2). The Zn1 site contains three histidine 1296 
residues (His116, His118, and His196), whereas the ligands for the Zn2 site are aspartic acid 1297 
(Asp120), cysteine (Cys221), and histidine (His263). There is only one zinc ion in the active site 1298 
of the A. hydrophila enzyme (subclass B2, panel B), and two in the active site of the S. 1299 
maltophilia enzyme (subclass B3, panel C).  1300 
 1301 
 1302 
 1303 
 1304 
 1305 
 1306 
 1307 
 1308 
 58 
 1309 
 1310 
 1311 
 59 
 1312 
